Wednesday 27th March 2019

(5 years, 1 month ago)

Westminster Hall
Read Full debate Read Hansard Text Read Debate Ministerial Extracts

Westminster Hall is an alternative Chamber for MPs to hold debates, named after the adjoining Westminster Hall.

Each debate is chaired by an MP from the Panel of Chairs, rather than the Speaker or Deputy Speaker. A Government Minister will give the final speech, and no votes may be called on the debate topic.

This information is provided by Parallel Parliament and does not comprise part of the offical record

Alex Norris Portrait Alex Norris (Nottingham North) (Lab/Co-op)
- Hansard - -

It is a pleasure to serve under your chairmanship, Sir Christopher. I, too, thank the right hon. Member for Arundel and South Downs (Nick Herbert) for not only securing the debate, but providing me with my first opportunity to respond from the Front Bench. He is very passionate about this topic, and that passion has been reflected in the contributions of every Member this afternoon.

Last week, along with many colleagues present in the Chamber, I attended an event in Speaker’s House on ending tuberculosis, where I was deeply moved by the impassioned words of Emily Wise, a doctor who had been on the front line of the battle against TB, working with Médecins Sans Frontières in Uzbekistan. She spoke of her trauma as she watched a patient die, and her anger at the fact that, as a doctor, she was unable to save her. The patient did not die for medical reasons; she did not die because Emily did not know how to save her, or because TB is incurable. Let me repeat Emily’s professional diagnosis of why her patient died. She said:

“In this modern age, all deaths from TB boil down to a lack of commitment from the international political community and the pharmaceutical industry to address this disease.”

Her message is clear: as politicians, we must do more. We have to step up to the challenge of ending the world’s deadliest infectious disease, and it is entirely within our reach to do so.

Sunday marked World TB Day: an occasion to remind ourselves of where we are in the fight to end TB. It has been curable for more than 50 years, yet in 2017 it killed 1.6 million people, and there were 10 million new infections, of which 3.6 million were never officially diagnosed or treated. It is a disease of inequality, with the poorest most at risk, and 95% of the deaths occur in low and middle-income countries. Here at home, the poorest 10% of people are at a seven times higher risk of contracting TB. According to the World Health Organisation, at the current rate of progress we will fail to reach the global goal of ending TB by 2030.

I am hopeful that the world might be beginning to wake up to that severe injustice. As we heard, last September the first UN high-level meeting on TB took place. Governments committed to significant investment for programmes and research. The meeting was clearly a step in the right direction, but we must now accelerate progress. We know that in order to effectively diagnose and treat TB, countries need a strong public health system. My hon. Friend the Member for Brighton, Kemptown (Lloyd Russell-Moyle) made that point very strongly.

In the UK, 81% of people who contract TB fully recover, thanks to our wonderful national health service. Does the Minister agree that the Department for International Development ought to focus on building strong public services, so that people’s right to access healthcare is not based on their ability to pay? Of course, getting people the treatment that they need also requires international funding. That is why we must ensure that the Global Fund is fully resourced and I, too, encourage the Government to make a commitment to increase the UK’s contribution to it.

Finally, let me address the issue of access to medicines. In all countries, there are now TB strains that are resistant to at least some of the treatments available. In recent years, new, highly effective medicines for multi-drug-resistant TB have been approved, but they are reaching only 5% of the people who need them. Among the barriers to access, affordability is a major concern—[Interruption.] Not now, please.

That lack of affordability is despite huge public investment from the UK and other sources into one of the drugs: bedaquiline. We have a crisis in the research and development system for medicines. I therefore ask the Minister whether DFID will commit to working with other Government Departments, and partners globally, to revisit the system of exclusive intellectual property rights that prevents drugs from getting to those who need them the most.

Parliamentarians last discussed TB nine months ago. It seems that not an awful lot has changed. I hope that when we are next together, we can reflect on more progress.